Advertisement

Human Papillomavirus Infection and Cancer Risk in Peri- and Postmenopausal Women

  • Pedro Vieira-Baptista
  • Mario Preti
  • Jacob Bornstein
Chapter

Abstract

Human papillomavirus (HPV) infection is a necessary cause of cervical cancer. Contrarily to most preinvasive cervical lesions, the majority of cancers occur in the perimenopause or early after the menopause. Nevertheless, around 15% of cervical cancers occur after 65 years old. There are data suggesting that screening beyond this age can decrease cervical cancer-associated mortality. Screening in postmenopausal women is better accomplished with the use of high-risk HPV tests. Atrophy with thinning of the epithelium and regression of the squamous cellular junction to the endocervix can make colposcopy in postmenopausal women a true challenge.

Prevalence of HPV infection decreases after the age of 25–30 years old, keeping stable from then on. In some countries, a later peak can be noticed in the fifth or six decade of life. Postmenopausal women are still at risk of acquiring new HPV infections, as well as of having reactivation of latent ones.

The burden of disease associated with HPV is not limited to the cervix. It is also responsible for a significant number of vulvar, vaginal, anal, and even oropharyngeal cancers—beside benign and preinvasive disease.

While HPV vaccination will totally change the epidemiology of HPV infection, vaccinating older women has a very limited role.

Keywords

Human papillomavirus (HPV) Vulvar intraepithelial neoplasia (VIN) Vaginal intraepithelial neoplasia (VaIN) Cervical cancer Vulvar cancer Menopause Pap test Colposcopy Screening High-grade squamous intraepithelial lesion (HSIL) 

References

  1. 1.
    Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE, et al. A review of human carcinogens—Part B: biological agents. Lancet Oncol. 2009;10(4):321–2.CrossRefGoogle Scholar
  2. 2.
    Denis F, Hanz S, Alain S. Clairance, persistance et récidive de l’infection à Papillomavirus. Gynecol Obstet Fertil. 2008;36(4):430–40.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Roehr B. Presence of HPV in later life may represent reactivation, not reinfection. BMJ. 2012;345:e8517.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Syrjänen K, Hakama M, Saarikoski S, Väyrynen M, Yliskoski M, Syrjänen S, et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis. 1990;17(1):15–9.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Mariani L, Preti M, Cristoforoni P, Stigliano CM, Perino A. Overview of the benefits and potential issues of the nonavalent HPV vaccine. Int J Gynaecol Obstet. 2017;136(3):258–65.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–65.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Brown DR, Weaver B. Human papillomavirus in older women: new infection or reactivation? J Infect Dis. 2013;207(2):211–2.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Gravitt PE, Rositch AF, Silver MI, Marks MA, Chang K, Burke AE, et al. A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis. 2013;207(2):272–80.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Gonzalez P, Hildesheim A, Rodriguez AC, Schiffman M, Porras C, Wacholder S, et al. Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3044–54.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Franceschi S, Herrero R, Clifford GM, Snijders PJF, Arslan A, Anh PTH, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119(11):2677–84.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Grainge MJ, Seth R, Guo L, Neal KR, Coupland C, Vryenhoef P, et al. Cervical human papillomavirus screening among older women. Emerg Infect Dis. 2005;11(11):1680–5.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Melkert PW, Hopman E, van den Brule AJ, Risse EK, van Diest PJ, Bleker OP, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is agedependent. Int J Cancer. 1993;53(6):919–23.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Gyllensten U, Gustavsson I, Lindell M, Wilander E. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 2012;125(2):343–5.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus–positive women. J Natl Cancer Inst. 2005;97(8):577–86.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Petry KU, Horn J, Luyten A, Mikolajczyk RT. Punch biopsies shorten time to clearance of high-risk human papillomavirus infections of the uterine cervix. BMC Cancer. 2018;18(1):318.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Bekos C, Schwameis R, Heinze G, Gärner M, Grimm C, Joura E, et al. Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Sci Rep. 2018;8(1):6383.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Olsen NJ, Kovaks WJ. Gonadal steroids and immunity. Endocr Rev. 1996;17(4):369–84.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Sakiani S, Olsen NJ, Kovacs WJ. Gonadal steroids and humoral immunity. Nat Rev Endocrinol. 2013;9(1):56–62.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Gameiro CM, Romão F, Castelo-Branco C. Menopause and aging: changes in the immune system—a review. Maturitas. 2010;67(4):316–20.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Stanley MA, Sterling JC. Host responses to infection with human papillomavirus. Curr Probl Dermatol. 2014;45:58–74.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Scherer EM, Smith RA, Gallego DF, Carter JJ, Wipf GC, Hoyos M, et al. A single human papillomavirus vaccine dose improves B cell memory in previously infected subjects. EBioMedicine. 2016;10:55–64.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315–24.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Ramachandran B. Functional association of oestrogen receptors with HPV infection in cervical carcinogenesis. Endocr Relat Cancer. 2017;24(4):R99–108.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Ferenczy A, Gelfand M, Franco E, Mansour N. Human papillomavirus infection in postmenopausal women with and without hormone therapy. Obstet Gynecol. 1997;90(1):7–11.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLoS One. 2016;11(1):e0147029.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Boonyanurak P, Panichakul S, Wilawan K. Prevalence of high-risk human papillomavirus infection (HPV) and correlation with postmenopausal hormonal therapy in Thai women aged more than 45 years old. J Med Assoc Thai. 2010;93(1):9–16.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Munger K. Are selective estrogen receptor modulators (SERMs) a therapeutic option for HPV-associated cervical lesions and cancers? Am J Pathol. 2014;184(2):358–61.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Rhodes HE, Chenevert L, Munsell M. Vaginal intraepithelial neoplasia (VaIN 2/3). J Low Genit Tract Dis. 2014;18(2):115–21.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Smith EM, Levy BT, Ritchie JM, Jia J, Wang D, Haugen TH, et al. Is use of hormone replacement therapy associated with increased detection of human papillomavirus and potential risk of HPV-related genital cancers? Eur J Cancer Prev. 2002;11(3):295–305.PubMedCrossRefGoogle Scholar
  31. 31.
    Clarke MA, Rodriguez AC, Gage JC, Herrero R, Hildesheim A, Wacholder S, et al. A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect Dis. 2012;12:33.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Kero K, Rautava J, Syrjänen K, Grenman S, Syrjänen S. Association of asymptomatic bacterial vaginosis with persistence of female genital human papillomavirus infection. Eur J Clin Microbiol Infect Dis. 2017;36(11):2215–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Vieira-Baptista P, Lima-Silva J, Pinto C, Saldanha C, Beires J, Martinez-de-Oliveira J, et al. Bacterial vaginosis, aerobic vaginitis, vaginal inflammation and major Pap smear abnormalities. Eur J Clin Microbiol Infect Dis. 2016;35:657–64.PubMedCrossRefGoogle Scholar
  34. 34.
    Hoffmann JN, You HM, Hedberg EC, Jordan JA, McClintock MK. Prevalence of bacterial vaginosis and Candida among postmenopausal women in the United States. J Gerontol Ser B Psychol Sci Soc Sci. 2014;69(Suppl 2):S205–14.CrossRefGoogle Scholar
  35. 35.
    Zhang H, Lu J, Lu Y, Cai Q, Liu H, Xu C. Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in China. Sci Rep. 2018;8(1):4923.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069.PubMedGoogle Scholar
  37. 37.
    Schwarz TF, Galaj A, Spaczynski M, Wysocki J, Kaufmann AM, Poncelet S, et al. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age. Cancer Med. 2017;6(11):2723–31.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Faubion SS, Larkin LC. Immunizations for adult women. Menopause. 2016;23(12):1345–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Preti M. VIN usual type—from the past to the future. Ecancermedicalscience. 2015;9:531.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Parker KH, Kemp TJ, Pan Y, Yang Z, Giuliano AR, Pinto LA. Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges. Vaccine. 2018;36(19):2705–11.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, et al. Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the Oral cavity: results from the mid-adult male vaccine trial. J Infect Dis. 2016;214(8):1276–83.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global cancer statistics, 2012. CA A Cancer J Clin. 2015;65(2):87–108.CrossRefGoogle Scholar
  43. 43.
    Garland SM, Giuliano A, Brotherton J, Moscicki AB, Stanley M, Kaufmann AM, et al. IPVS statement moving towards elimination of cervical cancer as a public health problem. Papillomavirus Res. 2018;5:87–8.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev. 2018;19(2):319–24.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Franceschi S, Clifford GM, Baussano I. Options for design of real-world impact studies of single-dose vaccine schedules. Vaccine. 2018;36(32 Pt A):4816–22.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Harper DM, Vierthaler SL. Next generation cancer protection: the bivalent HPV vaccine for females. ISRN Obstet Gynecol. 2011;2011:1–20.CrossRefGoogle Scholar
  47. 47.
    Oakley F, Desouki MM, Pemmaraju M, Gargano JM, Markowitz LE, Steinau M, et al. Trends in high-grade cervical Cancer precursors in the human papillomavirus vaccine era. Am J Prev Med. 2018;55(1):19–25.PubMedCrossRefGoogle Scholar
  48. 48.
    Halford J, Walker K-A, Duhig J. A review of histological outcomes from peri-menopausal and post-menopausal women with a cytological report of possible high grade abnormality: an alternative management strategy for these women. Pathology. 2010;42(1):23–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Patton AL, Duncan L, Bloom L, Phaneuf G, Zafar N. Atypical squamous cells, cannot exclude a high-grade intraepithelial lesion and its clinical significance in postmenopausal, pregnant, postpartum, and contraceptiveuse patients. Cancer. 2008;114(6):481–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Gilani SM, Mazzara PF. Cytohistologic correlation in premenopausal and postmenopausal women. Acta Cytol. 2013;57(6):575–80.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Bornstein J, Sideri M, Tatti S, Walker P, Prendiville W, Haefner HK, et al. 2011 terminology of the vulva of the International Federation for Cervical Pathology and Colposcopy. J Low Genit Tract Dis. 2012;16(3):290–5.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Cuzick J, Clavel C, Petry K-U, Meijer CJLM, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095–101.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Piccoli R, Mandato VD, Lavitola G, Acunzo G, Bifulco G, Tommaselli GA, et al. Atypical squamous cells and low squamous intraepithelial lesions in postmenopausal women: implications for management. Eur J Obstet Gynecol Reprod Biol. 2008;140(2):269–74.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Vieira-Baptista P, Sousa C, Saldanha C, Fonseca-Moutinho JA. Consenso da ASCCP 2012—o que traz de novo e implicações para o dia-a-dia. Acta Obs Ginecol Port. 2013;7(4):241–8.Google Scholar
  55. 55.
    Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4):829–46.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Zhao C, Austin R. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone. Gynecol Oncol. 2007;107(2):231–5.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Cuzick J, Thomas Cox J, Zhang G, Einstein MH, Stoler M, Trupin S, et al. Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions. Int J Cancer. 2013;132(4):959–66.PubMedCrossRefGoogle Scholar
  58. 58.
    Practice Bulletin No. 168. Obstet Gynecol. 2016;128(4):e111–30.Google Scholar
  59. 59.
    Rustagi AS, Kamineni A, Weinmann S, Reed SD, Newcomb P, Weiss NS. Cervical screening and cervical Cancer death among older women: a population-based, case-control study. Am J Epidemiol. 2014;179(9):1107–14.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Andrae B, Andersson TM-L, Lambert PC, Kemetli L, Silfverdal L, Strander B, et al. Screening and cervical cancer cure: population based cohort study. BMJ. 2012;344:e900.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Gage JC, Duggan MA, Nation JG, Gao S, Castle PE. Detection of cervical cancer and its precursors by endocervical curettage in 13,115 colposcopically guided biopsy examinations. Am J Obstet Gynecol. 2010;203(5):481.e1–9.CrossRefGoogle Scholar
  62. 62.
    Boulanger JC, Gondry J, Verhoest P, Capsie C, Najas S. Treatment of CIN after menopause. Eur J Obstet Gynecol Reprod Biol. 2001;95(2):175–80.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Richards A, Dalrymple C. Abnormal cervicovaginal cytology, unsatisfactory colposcopy and the use of vaginal estrogen cream: an observational study of clinical outcomes for women in low estrogen states. J Obstet Gynaecol Res. 2015;41(3):440–4.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Makkar B, Batra S, Gandhi G, Zutshi V, Goswami D. Vaginal misoprostol versus vaginal estradiol in overcoming unsatisfactory colposcopy. Gynecol Obstet Investig. 2014;77(3):176–9.CrossRefGoogle Scholar
  65. 65.
    Aggarwal R, Suneja A, Agarwal N, Mishra K. Role of misoprostol in overcoming an unsatisfactory colposcopy: a randomized double-blind placebo-controlled clinical trial. Gynecol Obstet Investig. 2006;62(2):115–20.CrossRefGoogle Scholar
  66. 66.
    Thanapprapasr D, Wilailak S, Ayudhya NIN, Lertkhachonsuk A-A, Likittanasombut P, Chittithaworn S, et al. Can vaginal misoprostol effectively increase rate of a satisfactory colposcopy? A randomized double-blind placebo-controlled trial. Jpn J Clin Oncol. 2010;40(3):203–7.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Boardman LA, Meinz H, Steinhoff MM, Heber WW, Blume J. A randomized trial of the sleeved cytobrush and the endocervical curette. Obstet Gynecol. 2003;101(3):426–30.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Tate K, Strickland J. A randomized controlled trial to evaluate the use of the endocervical brush after endocervical curettage. Obstet Gynecol. 1997;90(5):715–7.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Driggers RW, Zahn CM. To ECC or not to ECC: the question remains. Obstet Gynecol Clin North Am. 2008;35(4):583–97.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Irvin W, Flora S, Andersen W, Stoler M, Taylor P, Rice L. Endocervical curettage. Does it contribute to the management of patients with abnormal cervical cytology? J Reprod Med. 2004;49(1):1–7.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2013;(6):CD001318.Google Scholar
  72. 72.
    Fine BA, Feinstein GI, Sabella V. The pre- and postoperative value of endocervical curettage in the detection of cervical intraepithelial neoplasia and invasive cervical cancer. Gynecol Oncol. 1998;71(1):46–9.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Hasegawa K, Torii Y, Kato R, Udagawa Y, Fukasawa I. The problems of cervical conization for postmenopausal patients. Eur J Gynaecol Oncol. 2016;37(3):327–31.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Chen Y, Lu H, Wan X, Lv W, Xie X. Factors associated with positive margins in patients with cervical intraepithelial neoplasia grade 3 and postconization management. Int J Gynecol Obstet. 2009;107(2):107–10.CrossRefGoogle Scholar
  75. 75.
    Chambo Filho A, Garbeloto E, Guarconi JRA, Partele MP. Positive endocervical margins at conization: repeat conization or colposcopic follow-up? A retrospective study. J Clin Med Res. 2015;7(7):540–4.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Binyamin L, Segev M, Peled Y, Krissi H, Sabah G, Raban O, et al. Simple hysterectomy for residual cervical intraepithelial neoplasm. J Low Genit Tract Dis. 2018;22(2):126–8.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    González Bosquet E, Torres A, Busquets M, Esteva C, Muñoz-Almagro C, Lailla JM. Prognostic factors for the development of vaginal intraepithelial neoplasia. Eur J Gynaecol Oncol. 2008;29(1):43–5.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Arbyn M, Redman CWE, Verdoodt F, Kyrgiou M, Tzafetas M, Ghaem-Maghami S, et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 2017;18(12):1665–79.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Tanaka Y, Ueda Y, Kakuda M, Kubota S, Matsuzaki S, Iwamiya T, et al. Predictors for recurrent/persistent high-grade intraepithelial lesions and cervical stenosis after therapeutic conization: a retrospective analysis of 522 cases. Int J Clin Oncol. 2017;22(5):921–6.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Penna C, Fambrini M, Fallani MG, Pieralli A, Scarselli G, Marchionni M. Laser CO2 conization in postmenopausal age: risk of cervical stenosis and unsatisfactory follow-up. Gynecol Oncol. 2005;96(3):771–5.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Gosvig CF, Huusom LD, Andersen KK, Duun-Henriksen AK, Frederiksen K, Iftner A, et al. Long-term follow-up of the risk for cervical intraepithelial neoplasia grade 2 or worse in HPV-negative women after conization. Int J Cancer. 2015;137(12):2927–33.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Ceballos KM, Lee M, Cook DA, Smith LW, Gondara L, Krajden M, et al. Post–loop electrosurgical excision procedure high-risk human papillomavirus testing as a test of cure. J Low Genit Tract Dis. 2017;21(4):284–8.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Cubie HA, Canham M, Moore C, Pedraza J, Graham C, Cuschieri K. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). J Clin Pathol. 2014;67(6):458–63.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    RMF E, DWE R, IntHout J, WJG M, LFAG M, Bulten J, et al. Long-lasting increased risk of human papillomavirus–related carcinomas and premalignancies after cervical intraepithelial neoplasia grade 3: a population-based cohort study. J Clin Oncol. 2017;35(22):2542–50.CrossRefGoogle Scholar
  85. 85.
    Zhang J, Chang X, Qi Y, Zhang Y, Zhang S. A retrospective study of 152 women with vaginal intraepithelial neoplasia. Int J Gynecol Obstet. 2016;133(1):80–3.CrossRefGoogle Scholar
  86. 86.
    Sillman FH, Fruchter RG, Chen YS, Camilien L, Sedlis A, McTigue E. Vaginal intraepithelial neoplasia: risk factors for persistence, recurrence, and invasion and its management. Am J Obstet Gynecol. 1997;176(1 Pt 1):93–9.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Dodge JA, Eltabbakh GH, Mount SL, Walker RP, Morgan A. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol. 2001;83(2):363–9.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Diakomanolis E, Stefanidis K, Rodolakis A, Haidopoulos D, Sindos M, Chatzipappas I, et al. Vaginal intraepithelial neoplasia: report of 102 cases. Eur J Gynaecol Oncol. 2002;23(5):457–9.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Sopracordevole F, Barbero M, Clemente N, Fallani MG, Cattani P, Agarossi A, et al. Colposcopic patterns of vaginal intraepithelial neoplasia. Eur J Cancer Prev. 2018;27(2):152–7.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Ratnavelu N, Patel A, Fisher A, Galaal K, Cross P, Naik R. High-grade vaginal intraepithelial neoplasia: can we be selective about who we treat? BJOG. 2013;120(7):887–93.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Tainio K, Jakobsson M, Louvanto K, Kalliala I, Paavonen J, Nieminen P, et al. Randomised trial on treatment of vaginal intraepithelial neoplasia-imiquimod, laser vaporisation and expectant management. Int J Cancer. 2016;139(10):2353–8.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Sopracordevole F, Barbero M, Clemente N, Fallani MG, Cattani P, Agarossi A, et al. High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). Eur Rev Med Pharmacol Sci. 2016;20(5):818–24.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Sinno AK, Saraiya M, Thompson TD, Hernandez BY, Goodman MT, Steinau M, et al. Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. Obstet Gynecol. 2014;123(4):817–21.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Lilic V, Lilic G, Filipovic S, Visnjic M, Zivadinovic R. Primary carcinoma of the vagina. J BUON. 2010;15(2):241–7.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Pride GL, Buchler DA. Carcinoma of vagina 10 or more years following pelvic irradiation therapy. Am J Obstet Gynecol. 1977;127(5):513–7.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Dominiak-Felden G, Cohet C, Atrux-Tallau S, Gilet H, Tristram A, Fiander A. Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, healthrelated quality of life study in the UK. BMC Public Health. 2013;13(1):1065.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol. 2003;189(3 Suppl):S3–11.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Mayeaux EJ, Dunton C. Modern management of external genital warts. J Low Genit Tract Dis. 2008;12(3):185–92.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    van Beurden M, van der Vange N, de Craen AJ, Tjong-A-Hung SP, ten Kate FJ, ter Schegget J, et al. Normal findings in vulvar examination and vulvoscopy. Br J Obstet Gynaecol. 1997;104(3):320–4.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Chang L, Ci P, Shi J, Zhai K, Feng X, Colombara D, et al. Distribution of genital wart human papillomavirus genotypes in China: a multi-center study. J Med Virol. 2013;85(10):1765–74.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Howell-Jones R, Soldan K, Wetten S, Mesher D, Williams T, Gill ON, et al. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis. 2013;208(9):1397–403.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Vulvar cancer—cancer stat facts. https://seer.cancer.gov/statfacts/html/vulva.html.
  104. 104.
    Kurman RJ, American Registry of Pathology, Armed Forces Institute of Pathology (U.S.). Tumors of the cervix, vagina, and vulva. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology; 2010. p. 431.Google Scholar
  105. 105.
    Saraiya M, Watson M, Wu X, King JB, Chen VW, Smith JS, et al. Incidence of in situ and invasive vulvar cancer in the US, 1998-2003. Cancer. 2008;113(10 Suppl):2865–72.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Buttmann-Schweiger N, Klug SJ, Luyten A, Holleczek B, Heitz F, Du Bois A, et al. Incidence patterns and temporal trends of invasive nonmelanotic vulvar tumors in Germany 1999-2011. A population-based cancer registry analysis. PLoS One. 2015;10(5):e0128073.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Baandrup L, Varbo A, Munk C, Johansen C, Frisch M, Kjaer SK. In situ and invasive squamous cell carcinoma of the vulva in Denmark 1978-2007-a nationwide population-based study. Gynecol Oncol. 2011;122(1):45–9.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006;107(5):1018–22.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Bodelon C, Madeleine MM, Voigt LF, Weiss NS. Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control. 2009;20(9):1779–82.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Barlow EL, Kang Y-J, Hacker NF, Canfell K. Changing trends in vulvar cancer incidence and mortality rates in Australia since 1982. Int J Gynecol Cancer. 2015;25(9):1683–9.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Bornstein J, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl TG, Reutter J, ISSVD Terminology Committee. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. Obstet Gynecol. 2016;127(2):264–8.Google Scholar
  112. 112.
    Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med. 2005;50(11):807–10.PubMedPubMedCentralGoogle Scholar
  113. 113.
    Bornstein J, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl TG, et al. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. J Low Genit Tract Dis. 2016;20(1):11–4.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    De Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49(16):3450–61.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    van de Nieuwenhof HP, Massuger LFAG, van der Avoort IAM, Bekkers RLM, Casparie M, Abma W, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer. 2009;45(5):851–6.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    de Bie RP, van de Nieuwenhof HP, Bekkers RLM, Melchers WJG, Siebers a G, Bulten J, et al. Patients with usual vulvar intraepithelial neoplasia-related vulvar cancer have an increased risk of cervical abnormalities. Br J Cancer. 2009;101(1):27–31.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Preti M, Bucchi L, Ghiringhello B, Privitera S, Frau V, Corvetto E, et al. Risk factors for unrecognized invasive carcinoma in patients with vulvar high-grade squamous intraepithelial lesion at vulvoscopy-directed biopsy. J Gynecol Oncol. 2017;28(4):e27.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Bornstein J, Kaufman RH, Adam E, Adler-Storthz K. Multicentric intraepithelial neoplasia involving the vulva. Clinical features and association with human papillomavirus and herpes simplex virus. Cancer. 1988;62(8):1601–4.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    McAlpine JN, Kim SY, Akbari A, Eshragh S, Reuschenbach M, von Knebel Doeberitz M, et al. HPV-independent differentiated vulvar intraepithelial neoplasia (dVIN) is associated with an aggressive clinical course. Int J Gynecol Pathol. 2017;36(6):507–16.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice, American Society for Colposcopy and Cervical Pathology (ASCCP). Committee opinion no. 675. Obstet Gynecol. 2016;128(4):e178–82.CrossRefGoogle Scholar
  121. 121.
    Kokka F, Singh N, Faruqi A, Gibbon K, Rosenthal AN. Is differentiated vulval intraepithelial neoplasia the precursor lesion of human papillomavirus-negative vulval squamous cell carcinoma? Int J Gynecol Cancer. 2011;21(7):1297–305.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Preti M, Scurry J, Marchitelli CE, Micheletti L. Vulvar intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1051–62.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Terlou A, Van Seters M, Ewing PC, Aaronson NK, Gundy CM, Heijmans-Antonissen C, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol. 2011;121(1):157–62.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Hurt CN, Jones SEF, Madden T, Fiander A, Nordin AJ, Naik R, et al. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN). BJOG. 2018;25(9):1171–7.CrossRefGoogle Scholar
  125. 125.
    Dellinger TH, Hakim AA, Lee SJ, Wakabayashi MT, Morgan RJ, Han ES. Surgical management of vulvar cancer. J Natl Compr Cancer Netw. 2017;15(1):121–8.CrossRefGoogle Scholar
  126. 126.
    Micheletti L, Preti M. Surgery of the vulva in vulvar cancer. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1074–87.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Baiocchi G, Rocha RM. Vulvar cancer surgery. Curr Opin Obstet Gynecol. 2014;26(1):9–17.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Preti M, Rouzier R, Mariani L, Wilkinson EJ. Superficially invasive carcinoma of the vulva: diagnosis and treatment. Clin Obstet Gynecol. 2005;48(4):862–8.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Zhou J, Shan G. The prognostic role of FIGO stage in patients with vulvar cancer: a systematic review and meta-analysis. Curr Med Res Opin. 2016;32(6):1121–30.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Luchini C, Nottegar A, Solmi M, Sergi G, Manzato E, Capelli P, et al. Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: a systematic review and meta-analysis. Surg Oncol. 2016;25(1):60–5.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Hudson CN, Shulver H, Lowe DC. The surgery of “inguino-femoral” lymph nodes: is it adequate or excessive? Int J Gynecol Cancer. 2004;14(5):841–5.PubMedPubMedCentralGoogle Scholar
  132. 132.
    Te Grootenhuis NC, Van Der Zee AGJ, Van Doorn HC, Van Der Velden J, Vergote I, Zanagnolo V, et al. Sentinel nodes in vulvar cancer: long-term follow-up of the GROningen INternational study on sentinel nodes in vulvar cancer (GROINSS-V) i. Gynecol Oncol. 2016;140(1):8–14.CrossRefGoogle Scholar
  133. 133.
    Aragona AM, Soderini AH, Cuneo NA. Defining the concept of locally advanced squamous cell carcinoma of the vulva: a new perspective based on standardization of criteria and current evidence. J Gynecol Oncol. 2014;25(4):272–8.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Kellas-Śleczka S, Białas B, Fijałkowski M, Wojcieszek P, Szlag M, Cholewka A, et al. Interstitial high-dose-rate brachytherapy in locally advanced and recurrent vulvar cancer. J Contemp Brachytherapy. 2016;8(1):32–40.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Natesan D, Hong JC, Foote J, Sosa JA, Havrilesky L, Chino J. Primary versus preoperative radiation for locally advanced vulvar cancer. Int J Gynecol Cancer. 2017;27(4):794–804.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Gill BS, Bernard ME, Lin JF, Balasubramani GK, Rajagopalan MS, Sukumvanich P, et al. Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: a National Cancer Data Base (NCDB) analysis. Gynecol Oncol. 2015;137(3):365–72.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Oonk MHM, Planchamp F, Baldwin P, Bidzinski M, Brännström M, Landoni F, et al. European Society of Gynaecological Oncology guidelines for the management of patients with vulvar cancer. Int J Gynecol Cancer. 2017;27(4):832–7.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Cao H, Wang S, Zhang Z, Lou J. Prognostic value of overexpressed p16INK4a in vulvar cancer: a meta-analysis. PLoS One. 2016;11(3):e0152459.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Tringler B, Grimm C, Dudek G, Zeillinger R, Tempfer C, Speiser P, et al. p16INK4a expression in invasive vulvar squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2007;15(3):279–83.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Dong F, Kojiro S, Borger DR, Growdon WB, Oliva E. Squamous cell carcinoma of the vulva: a subclassification of 97 cases by clinicopathologic, immunohistochemical, and molecular features (p16, p53, and EGFR). Am J Surg Pathol. 2015;39(8):1045–53.PubMedCrossRefGoogle Scholar
  141. 141.
    Rakislova N, Saco A, Sierra A, del Pino M, Ordi J. Role of human papillomavirus in vulvar cancer. Adv Anat Pathol. 2017;24(4):201–14.PubMedCrossRefGoogle Scholar
  142. 142.
    Moscicki A-B, Darragh TM, Berry-Lawhorn JM, Roberts JM, Khan MJ, Boardman LA, et al. Screening for anal cancer in women. J Low Genit Tract Dis. 2015;19:S26–41.PubMedCentralCrossRefGoogle Scholar
  143. 143.
    Acevedo-Fontánez AI, Suárez E, Torres Cintrón CR, Ortiz AP. Risk of anal cancer in women with a human papillomavirus–related gynecological neoplasm. J Low Genit Tract Dis. 2018;22(3):225–30.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Hillman RJ, Cuming T, Darragh T, Nathan M, Berry-Lawthorn M, Goldstone S, et al. 2016 IANS International guidelines for practice standards in the detection of anal cancer precursors. J Low Genit Tract Dis. 2016;20(4):283–91.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
    Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer. 2012;130(5):1168–73.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
  147. 147.
    Vokes EE, Agrawal N, Seiwert TY. HPV-associated head and neck cancer. J Natl Cancer Inst. 2015;107(12):djv344.PubMedCrossRefPubMedCentralGoogle Scholar
  148. 148.
    Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319–31.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 149.
    Hübbers CU, Akgül B. HPV and cancer of the oral cavity. Virulence. 2015;6(3):244–8.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–51.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Ortiz AP, González D, Vivaldi-Oliver J, Castañeda M, Rivera V, Díaz E, et al. Periodontitis and oral human papillomavirus infection among hispanic adults. Papillomavirus Res. 2018;5:128–33.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Woo S-B, Cashman EC, Lerman MA. Human papillomavirus-associated oral intraepithelial neoplasia. Mod Pathol. 2013;26(10):1288–97.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Gipson BJ, Robbins HA, Fakhry C, D’Souza G. Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer. Oral Oncol. 2018;77:52–6.PubMedCrossRefGoogle Scholar
  154. 154.
    Chan PKS, Chang AR, Yu MY, Li W-H, Chan MYM, Yeung ACM, et al. Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. Int J Cancer. 2010;126(1):297–301.PubMedCrossRefGoogle Scholar
  155. 155.
    Key statistics for cervical cancer [Internet]. https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html.
  156. 156.
    Watson AJM, Smith BB, Whitehead MR, Sykes PH, Frizelle FA. Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg. 2006;76(8):715–7.PubMedCrossRefGoogle Scholar
  157. 157.
    Scholefield JH, Castle MT, Watson NFS. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg. 2005;92(9):1133–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Pedro Vieira-Baptista
    • 1
    • 2
  • Mario Preti
    • 3
  • Jacob Bornstein
    • 4
  1. 1.Hospital Lusíadas PortoPortoPortugal
  2. 2.Lower Genital Tract UnitCentro Hospitalar de São JoãoPortoPortugal
  3. 3.Department of Obstetrics and GynecologySant’Anna Hospital, University of TorinoTurinItaly
  4. 4.Department of Obstetrics and GynecologyGalilee Medical Center, Nahariya and Azrieli Faculty of Medicine, Bar Ilan UniversitySafedIsrael

Personalised recommendations